Voydeya
Voydeya ingredients
| Active ingredient | Strength |
|---|---|
| Danicopan | 100 mg/1 |
What Voydeya is used for
The FDA lists the approved uses on the official label (below). In the EU, danicopan is approved as Voydeya for:
Voydeya is indicated as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Voydeya
- Generic name
- Danicopan
- Made by
- Alexion Pharmaceuticals Inc.
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Complement Factor D Inhibitor
- FDA approval
- New drug application (NDA) NDA218037
- On the US market since
- 2024
Official information
- Voydeya prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Danicopan)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Voydeya?
Voydeya (Danicopan) is a specialist medicine made by Alexion Pharmaceuticals Inc., approved by the US FDA.
What are the ingredients of Voydeya?
Voydeya contains Danicopan (100 mg/1).
Is Voydeya approved in Europe?
The same active substance is approved in the EU as Voydeya.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA